Pérez-Carbonell L, Mignot E, Leschziner G, et al. Understanding and approaching excessive daytime sleepiness. Lancet. 2022;400(10357):1033–46.

Article  PubMed  Google Scholar 

Lal C, Weaver TE, Bae CJ, et al. Excessive daytime sleepiness in obstructive sleep apnea: mechanisms and clinical management. Ann Am Thorac Soc. 2021;18(5):757–68.

Article  PubMed  PubMed Central  Google Scholar 

Ono T, Takenoshita S, Nishino S. Pharmacologic management of excessive daytime sleepiness. Sleep Med Clin. 2022;17(3):485–503.

Article  PubMed  Google Scholar 

Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367–76.

Article  CAS  PubMed  Google Scholar 

TMC Pharma (EU) Ltd. Sunosi (solriamfetol) film-coated tablets: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi. Accessed 6 Sep 2023.

Axsome Therapeutics Inc. SUNOSI (solriamfetol) tablets, for oral use: US prescribing information. 2023. https://www.fda.gov/. Accessed 6 Sep 2023.

Markham A. Solriamfetol: first global approval. Drugs. 2019;79(7):785–90.

Article  CAS  PubMed  Google Scholar 

Deeks ED, Heo YA. Solriamfetol in excessive daytime sleepiness: a profile of its use. Drugs Ther Perspect. 2020;36(5):173–80.

Article  Google Scholar 

Zomorodi K, Chen D, Lee L, et al. A randomized, double-blind, placebo- and positive-controlled, 4-period crossover study of the effects of solriamfetol on QTcF intervals in healthy participants. Clin Pharmacol Drug Dev. 2021;10(4):404–13.

Article  CAS  PubMed  Google Scholar 

Carter LP, Henningfield JE, Wang YG, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zomorodi K, Chen D, Lee L, et al. Single-dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019;59(8):1120–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102–8.

Article  PubMed  Google Scholar 

Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379–87.

Article  PubMed  PubMed Central  Google Scholar 

Strollo PJ Jr, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019;155(2):364–74.

Article  PubMed  Google Scholar 

Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2019;199(11):1421–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malhotra A, Shapiro C, Pepin JL, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep. 2020;43(2):1–11.

Article  Google Scholar 

European Medicines Agency. Sunosi (international non-proprietary name solriamfetol): EU assessment report. 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi. Accessed 6 Sep 2023.

Krystal AD, Benca RM, Rosenberg R, et al. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. J Psychiatr Res. 2022;155:202–10.

Article  PubMed  PubMed Central  Google Scholar 

Dauvilliers Y, Shapiro C, Mayer G, et al. Solriamfetol for the treatment of excessive daytime sleepiness in participants with narcolepsy with and without cataplexy: subgroup analysis of efficacy and safety data by cataplexy status in a randomized controlled trial. CNS Drugs. 2020;34(7):773–84.

Article  CAS  PubMed  Google Scholar 

Emsellem HA, Thorpy MJ, Lammers GJ, et al. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. Sleep Med. 2020;67:128–36.

Article  PubMed  Google Scholar 

Schweitzer PK, Mayer G, Rosenberg R, et al. Randomized controlled trial of solriamfetol for excessive daytime sleepiness in OSA: an analysis of subgroups adherent or nonadherent to OSA treatment. Chest. 2021;160(1):307–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weaver TE, Drake CL, Benes H, et al. Effects of solriamfetol on quality-of-life measures from a 12-week phase 3 randomized controlled trial. Ann Am Thorac Soc. 2020;17(8):998–1007.

Article  PubMed  PubMed Central  Google Scholar 

Schweitzer PK, Strohl KP, Mayer G, et al. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. J Clin Sleep Med. 2021;17(4):659–68.

Article  PubMed  PubMed Central  Google Scholar 

Weaver TE, Pepin JL, Schwab R, et al. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021;17(10):1995–2007.

Article  PubMed  PubMed Central  Google Scholar 

Winter Y, Mayer G, Kotterba S, et al. Solriamfetol real world experience study (SURWEY): initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany. Sleep Med. 2023;103:138–43.

Article  PubMed  Google Scholar 

Malhotra A, Strollo PJ, Pepin J-L, et al. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. Sleep Med. 2022;100:165–73.

Article  PubMed  PubMed Central  Google Scholar 

Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28(9):2815–30.

Article  PubMed  Google Scholar 

Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–93.

Article  PubMed  PubMed Central  Google Scholar 

Gandhi KD, Mansukhani MP, Silber MH, et al. Excessive daytime sleepiness: a clinical review. Mayo Clin Proc. 2021;96(5):1288–301.

Article  CAS  PubMed  Google Scholar 

Bioprojet Pharma. Wakix (pitolisant) film-coated tablets: EU summary of product characteristics. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/wakix. Accessed 6 Sep 2023.

UCB Pharma SA. Xyrem (sodium oxybate) 500 mg/mL oral solution: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem. Accessed 6 Sep 2023.

European Medicines Agency. Modafinil-containing medicinal products: annex I, II, III, IV. 2011. https://www.ema.europa.eu/en/medicines/human/referrals/modafinil. Accessed 6 Sep 2023.

Teva Pharmaceuticals USA Inc. PROVIGIL® (modafinil) tablets, for oral use, C-IV: US prescribing information. 2015. https://www.fda.gov/. Accessed 6 Sep 2023.

Jazz Pharmaceuticals Inc. XYREM® (sodium oxybate) oral solution, CIII: US prescribing information. 2023. https://www.fda.gov/. Accessed 6 Sep 2023.

Harmony Biosciences LLC. WAKIX® (pitolisant) tablets, for oral use: US prescribing information. 2022. https://www.fda.gov/. Accessed 6 Sep 2023.

Teva Pharmaceuticals USA Inc. NUVIGIL® (armodafinil) tablets, for oral use, C-IV: US prescribing information. 2017. https://www.fda.gov/. Accessed 6 Sep 2023.

Rosenberg R, Schweitzer PK, Steier J, et al. Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management. Postgrad Med. 2021;133(7):772–83.

Article  PubMed  Google Scholar 

Randerath W, Verbraecken J, de Raaff CAL, et al. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. Eur Respir Rev. 2021;30(162): 210200.

Article  PubMed  PubMed Central  Google Scholar 

Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263–76.

Article  PubMed  Google Scholar 

Bioprojet Pharma. Ozawade (pitolisant) film-coated tablets: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade. Accessed 6 Sep 2023.

Pitre T, Mah J, Roberts S, et al. Comparative efficacy and safety of wakefulness-promoting agents for excessive daytime sleepiness in patients with obstructive sleep apnea: a systematic review and network meta-analysis. Ann Intern Med. 2023;176(5):676–84.

Article  PubMed  Google Scholar 

Zhan S, Ye H, Li N, et al. Comparative efficacy and safety of multiple wake-promoting agents for the treatment of excessive daytime sleepiness in narcolepsy: a network meta-analysis. Nat Sci Sleep. 2023;15:217–30.

Article  PubMed  PubMed Central  Google Scholar 

Chien PY, Kuo CY, Lin MH, et al. Pharmacological interventions for excessive daytime sleepiness in adults with narcolepsy: a systematic review and network meta analysis. J Clin Med. 2022;11(21):6302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ronnebaum S, Bron M, Patel D, et al. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. J Clin Sleep Med. 2021;17(12):2543–55.